Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients.

Trial Profile

Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Levofloxacin (Primary) ; Tobramycin
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Mpex Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results of pooled prespecified analysis of MPEX204,MPEX207 and MPEX209 studies presented at the 113th International Conference of the American Thoracic Society.
    • 10 Jun 2016 Results presented at the 39th European Cystic Fibrosis Conference 2016, according to a Raptor Pharmaceutical Corp. media release.
    • 10 Jun 2016 Results published in a Raptor Pharmaceutical Corp. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top